Patient-derived organoids as predictor of clinical response in ovarian cancer: a systematic review
Merel Vegter, Prakriti Garkhail, Gatske M. Nieuwenhuyzen-de Boer, Ingrid A. Boere, Heleen J. van Beekhuizen · 2026
Read Patient-derived organoids as predictor of clinical response in ovarian cancer: a systematic review by Merel Vegter, Prakriti Garkhail, Gatske M. Nieuwenhuyzen-de Boer, Ingrid A. Boere, Heleen J. van Beekhuizen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13572739.txt.
Description
Merel Vegter and co-authors reviewed in 2026 whether lab-grown tumor organoids can predict how a woman's ovarian cancer will answer treatment. These patient-derived mini-tumors are drugged in a dish and matched against the patient's real course. Twelve studies, from 2019 on, met their bar, most of them small and retrospective.
Four studies found statistically firm links between dish and patient responses, and six more agreed without formal tests. The two prospective studies reported accuracy near ninety percent. But cohorts ran as small as six patients, and endpoints wandered from scans to survival. The authors call the signal promising and the evidence thin. Standardized prospective trials, they say, must come before clinics can trust the dish.
Catalog record
| CREATOR | Merel Vegter, Prakriti Garkhail, Gatske M. Nieuwenhuyzen-de Boer, Ingrid A. Boere, Heleen J. van Beekhuizen |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 51 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |